The Roche ECLIA assay starts by introducing antibodies that are designed to bind specifically to the what’s being tested for (in this case estradiol). The antigen also has a ruthenium molecule attached to it that can emit light with electrical current (through electron excitation). The amount of light that is emitted later reveals the concentration of the compound being tested for such that the more light detected, the lower the concentration. But here’s where tren causes problems…
While the antibodies are very specific to estradiol in this particular test, there is cross-reactivity and roughly 0.1% will bind to trenbolone. Doesn’t sound like much, but trenbolone’s structure reduces the excitability of the ruthenium complex from before, meaning it takes more electricity (and thus electrons flowing through) to generate any light. Remember, the less light emitted, the higher the concentration of E2 is thought to exist with this method.
Next, these tiny magnetic beads that are coated with a streptavidin protein are added to the blood. These beads bind to the estradiol and some of the tren that already attached to the first antibody added (with the ruthenium that emits light under electrical current).
Now before the electricity flows to detect light, another compound is introduced in a known quantity. in this case, it is more estradiol that has already been “biotinylated” (estradiol with a vitamin b7 attached to it). Biotin and streptavidin are extremely attracted to each other, so this new estradiol (that will not emit light) competes with the existing estradiol to bind to the magnetic beads. The idea is that the more estradiol that was already in the blood, the more of this new labeled estradiol gets competed off and because this alters the total light emission, you can extrapolate how much estradiol was in the sample originally.
Unfortunately, the tren doesn’t ever lose its fight to keep its little microbead against the biotinylated estradiol because tren is king. And as reactions continue, more and more tren ends up swooping in and dominating like the alpha that it is.
Finally, a magnetic plate pulls all of the compounds that matter out of the solution, and the rest of the blood is washed away, including your true estradiol levels.
While the antibodies are very specific to estradiol in this particular test, there is cross-reactivity and roughly 0.1% will bind to trenbolone. Doesn’t sound like much, but trenbolone’s structure reduces the excitability of the ruthenium complex from before, meaning it takes more electricity (and thus electrons flowing through) to generate any light. Remember, the less light emitted, the higher the concentration of E2 is thought to exist with this method.
Next, these tiny magnetic beads that are coated with a streptavidin protein are added to the blood. These beads bind to the estradiol and some of the tren that already attached to the first antibody added (with the ruthenium that emits light under electrical current).
Now before the electricity flows to detect light, another compound is introduced in a known quantity. in this case, it is more estradiol that has already been “biotinylated” (estradiol with a vitamin b7 attached to it). Biotin and streptavidin are extremely attracted to each other, so this new estradiol (that will not emit light) competes with the existing estradiol to bind to the magnetic beads. The idea is that the more estradiol that was already in the blood, the more of this new labeled estradiol gets competed off and because this alters the total light emission, you can extrapolate how much estradiol was in the sample originally.
Unfortunately, the tren doesn’t ever lose its fight to keep its little microbead against the biotinylated estradiol because tren is king. And as reactions continue, more and more tren ends up swooping in and dominating like the alpha that it is.
Finally, a magnetic plate pulls all of the compounds that matter out of the solution, and the rest of the blood is washed away, including your true estradiol levels.
